scispace - formally typeset
M

Michael Bachmann

Researcher at Helmholtz-Zentrum Dresden-Rossendorf

Publications -  402
Citations -  16252

Michael Bachmann is an academic researcher from Helmholtz-Zentrum Dresden-Rossendorf. The author has contributed to research in topics: Antigen & Chimeric antigen receptor. The author has an hindex of 63, co-authored 360 publications receiving 14388 citations. Previous affiliations of Michael Bachmann include ACADIA Pharmaceuticals Inc. & University of Southern California.

Papers
More filters
Journal ArticleDOI

Multimodal PET/MRI Imaging Results Enable Monitoring the Side Effects of Radiation Therapy

TL;DR: A sensitive multimodal imaging protocol seems to be an appropriate method for follow-up of the health status after radiation therapy and makes possible parallel screening of healthy tissues and the effectiveness of tumor therapy without any additional radiation exposure.
Proceedings ArticleDOI

Patterning process exploration of metal 1 layer in 7nm node with 3D patterning flow simulations

TL;DR: In this paper, a simulation tool that enables emulation of the whole patterning flow with realistic process-dependent 3D profile and topology has been proposed to study the patterning process variations of N7 M1 layer including the overlay control, the critical dimension uniformity (CDU) budget and the lithographic process window.
Journal ArticleDOI

Development and Functional Characterization of a Versatile Radio-/Immunotheranostic Tool for Prostate Cancer Management

TL;DR: The favorable pharmacological profile of the anti-PSCA IgG4-TM, and its usage for imaging, targeted alpha therapy, and UniCAR T cell immunotherapy underlines the promising radio-/immunotheranostic capabilities for the diagnostic imaging and treatment of PCa.
Journal ArticleDOI

Chimeric Antigen Receptor-Engineered T Cells for Immunotherapy of Acute Myeloid Leukemia

TL;DR: A new method based on a novel CAR-mediated strategy was developed for an efficient in vitro expansion restricted to CAR modified T cells from patients, which efficiently killed AML blasts derived from patients.